12:53 PM EDT, 09/05/2024 (MT Newswires) -- Immuron ( IMRN ) said Thursday it plans to launch a phase 2 trial of IMM-529 in individuals with Clostridioides difficile infection after it received favorable feedback from the US Food and Drug Administration on the pre-investigational new drug information package for IMM-529.

The phase 2 trial will come after the drugmaker's expected filing of an investigational new drug application for IMM-529 in H1 of 2025, Immuron ( IMRN ) said.

Clostridioides difficile is a bacterium that causes diarrhea and inflammation of the colon.

Shares of Immuron ( IMRN ) fell 9.7% in recent trading.

Price: 2.42, Change: -0.26, Percent Change: -9.70